Hikma Pharmaceuticals Plc

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00B0LCW083
GBP
12.54
-0.34 (-2.64%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

5.76 M

Shareholding (Jun 2025)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

High Management Efficiency with a high ROCE of 18.66%

 
2

Company has a low Debt to Equity ratio (avg) at times

 
3

Positive results in Jun 25

4

With ROE of 13.78%, it has a very expensive valuation with a 1.45 Price to Book Value

5

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 2,893 Million (Mid Cap)

stock-summary
P/E

11.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.29%

stock-summary
Debt Equity

0.50

stock-summary
Return on Equity

13.78%

stock-summary
Price to Book

1.56

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.95%
0%
-16.95%
6 Months
-23.35%
0%
-23.35%
1 Year
-39.07%
0%
-39.07%
2 Years
-33.4%
0%
-33.4%
3 Years
-24.57%
0%
-24.57%
4 Years
-39.13%
0%
-39.13%
5 Years
-43.18%
0%
-43.18%

Hikma Pharmaceuticals Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
6.43%
EBIT Growth (5y)
-3.24%
EBIT to Interest (avg)
7.98
Debt to EBITDA (avg)
1.03
Net Debt to Equity (avg)
0.45
Sales to Capital Employed (avg)
0.81
Tax Ratio
20.49%
Dividend Payout Ratio
48.77%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
18.66%
ROE (avg)
16.01%

Valuation key factors

Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
1.45
EV to EBIT
9.46
EV to EBITDA
6.66
EV to Capital Employed
1.30
EV to Sales
1.46
PEG Ratio
7.29
Dividend Yield
1.65%
ROCE (Latest)
13.74%
ROE (Latest)
13.78%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Bearish
Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Hikma Pharmaceuticals Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 5.81% vs 13.19% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 83.37% vs -0.39% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,447.20",
          "val2": "2,312.90",
          "chgp": "5.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "629.20",
          "val2": "548.60",
          "chgp": "14.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "68.90",
          "val2": "70.00",
          "chgp": "-1.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-39.10",
          "val2": "-98.10",
          "chgp": "60.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "283.30",
          "val2": "154.50",
          "chgp": "83.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "194.10%",
          "val2": "170.80%",
          "chgp": "2.33%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
2,447.20
2,312.90
5.81%
Operating Profit (PBDIT) excl Other Income
629.20
548.60
14.69%
Interest
68.90
70.00
-1.57%
Exceptional Items
-39.10
-98.10
60.14%
Consolidate Net Profit
283.30
154.50
83.37%
Operating Profit Margin (Excl OI)
194.10%
170.80%
2.33%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 5.81% vs 13.19% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 83.37% vs -0.39% in Dec 2023

stock-summaryCompany CV
About Hikma Pharmaceuticals Plc stock-summary
stock-summary
Hikma Pharmaceuticals Plc
Pharmaceuticals & Biotechnology
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 300 products in different dosage strengths and forms. The Company's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.
Company Coordinates stock-summary
Company Details
1 New Burlington Place , LONDON None : W1S 2HR
stock-summary
Tel: 44 20 73992760
stock-summary
Registrar Details